UAB: Altimmune’s Intranasal COVID Vaccine Candidate Shows Sterilizing Immunity in Preclinical Tests

Published on : Published by : BioBuzz Media

University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.

Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate

Published on : Published by : BioBuzz Media

Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate Intranasal administration targets the virus at its point of entry and in a [….]